• With an initial market cap of €450m, Biocartis' IPO on Euronext Brussels is the largest Life Sciences IPO on Euronext since 2005
  • Proceeds of the IPO will be used to support R&D and to strengthen sales & marketing capabilities
  • Kempen & Co acted as Joint Bookrunner in the offering with demand exceeding €650m